Gilead Sciences is trading at ARS 64,650, up +8.66%, with the move most plausibly tied to its Vir Biotechnology oncology deal. - Announced October 14, it covers three solid-tumor T-cell engager candidates. - Gilead receives exclusive development and commercialization rights; Vir is eligible for $90 million upfront and up to $1.74 billion in further milestones. - October 15 coverage cited the deal as likely catalyst; live price is specific to GILD.BA, not U.S. market quotes.